

RESEARCH MONOGRAPH . COMPOUND PROFILE

Seltorexant

A selective orexin-2 receptor antagonist developed by Janssen Pharmaceuticals and Minerva Neurosciences as an adjunctive treatment for major depressive disorder with insomnia symptoms, distinguished from dual orexin receptor antagonists by its high OX2R selectivity, rapid pharmacokinetic profile, and demonstrated antidepressant efficacy through modulation of orexinergic hyperarousal.

DOCUMENT	KDC-MN-1526
ISSUED	2026-05-15
REVISION	1.0
AUTHOR	Kodiac bioLabs Research
COMPOUND CLASS	Selective orexin-2 receptor antagonist (2-SORA) with antidepressant and sleep-promoting activity

ABSTRACT

Seltorexant (JNJ-42847922, MIN-202) is a selective, high-affinity antagonist of the orexin-2 receptor (OX2R) and the first selective 2-SORA to advance through Phase 3 clinical trials for major depressive disorder (MDD) with insomnia symptoms. The compound exhibits approximately 100-fold selectivity for OX2R over OX1R and negligible affinity for other receptors, transporters, or ion channels in a panel of 50 assays, a selectivity profile that distinguishes it mechanistically from the dual orexin receptor antagonists (DORAs) suvorexant, lemborexant, and daridorexant approved for primary insomnia. Pharmacokinetics are characterized by rapid oral absorption (median time to maximum plasma concentration 0.3 to 1.5 hours), a short elimination half-life of approximately 2 to 3 hours, and metabolism predominantly through cytochrome P450 3A4, producing a pharmacokinetic profile suited to bedtime administration with minimal next-day residual effects. Preclinical pharmacology in rodent models demonstrated dose-dependent increases in non-rapid eye movement (NREM) sleep duration, reduced sleep onset latency, attenuation of stress-induced adrenocorticotrophic hormone (ACTH) release, suppression of hypothalamic-pituitary-adrenal (HPA) axis activation, and absence of effects on dopaminergic reward pathways or motor coordination. The specificity of these effects for OX2R was confirmed by the absence of activity in OX2R knockout mice. Brain penetration and receptor occupancy were confirmed by positron emission tomography imaging in rats and by in vivo competitive radioligand binding studies. The clinical evidence base spans Phase 1 through Phase 3 development. The Phase 1b

study in 47 patients with MDD (Recourt et al. 2019) demonstrated statistically significant improvement in core depressive symptoms on the Hamilton Depression Rating Scale (HDRS17) and HAM-D6 subscale compared to placebo at 20 mg daily for 10 to 28 days, with concordant changes in sleep electroencephalography spectral power. The Phase 2b adaptive dose-finding study (Savitz et al. 2021) in 283 patients with MDD and inadequate response to SSRI or SNRI therapy reported statistically significant improvement in Montgomery-Asberg Depression Rating Scale (MADRS) total score, MADRS-6 core symptom subscale, Insomnia Severity Index, and PROMIS Sleep Disturbance at the 20 mg dose, with response rates of 41.0 percent versus 28.5 percent on placebo and remission rates of 29.5 percent versus 19.0 percent. The pivotal Phase 3 MDD3001 trial achieved its primary and all secondary endpoints, with seltorexant 20 mg adjunctive to SSRI or SNRI producing a statistically significant least-squares mean difference from placebo of negative 2.6 points on MADRS total score at day 43 ($p = 0.007$) and significant improvement in PROMIS Sleep Disturbance (negative 3.7, $p < 0.001$). The Phase 3 MDD3005 active-comparator study against quetiapine extended-release demonstrated a numerically higher response rate for seltorexant (57.4 percent versus 53.4 percent) that did not reach statistical significance, but with substantially fewer adverse events, lower somnolence incidence (6 percent versus 24 percent), and markedly less weight gain (0.5 kg versus 2.1 kg over 26 weeks). A separate monotherapy Phase 1b study (2024) in 128 MDD patients demonstrated antidepressant activity independent of adjunctive SSRI or SNRI use. The compound is well tolerated across the clinical program. The most common treatment-emergent adverse events are headache, somnolence, and nausea at incidences comparable to placebo. No deaths, serious

treatment-emergent adverse events, clinically significant cardiovascular changes, or suicidal behavior events have been reported in the seltorexant treatment arms. No cataplexy has been observed. The compound does not produce conditioned place preference in mice, does not increase extracellular dopamine release in rat nucleus accumbens, and does not impair motor coordination at sleep-promoting doses, supporting a favorable abuse liability and safety profile relative to benzodiazepines and Z-drugs. Seltorexant has not yet received regulatory approval in any jurisdiction. Phase 3 clinical trials for adjunctive MDD with insomnia symptoms are ongoing, and Phase 2 investigation for primary insomnia and Alzheimer's disease is in progress. This monograph reviews the chemistry, synthesis, molecular pharmacology, pharmacokinetics, preclinical and clinical evidence base, sourcing and handling, stack interactions, adverse-event profile, and a comparative assessment of five orexin receptor antagonist candidates against seltorexant on five competency standards.

1. Compound Identification

1.1 Names, synonyms, and registry identifiers

International Nonproprietary Name: Seltorexant.

Development codes: JNJ-42847922, JNJ-922, MIN-202, MIN202. The JNJ-42847922 designation is the canonical identifier in the preclinical and early clinical pharmacology literature, first appearing in the Bonaventure et al. (2015) characterization report [1]. The MIN-202 designation reflects the licensing agreement with Minerva Neurosciences.

Chemical Abstracts Service registry number: 1293281-49-8 (free base).

International Union of Pure and Applied Chemistry name: (2-(4,6-dimethylpyrimidin-2-yl)-1,3,3a,4,6,6a-hexahydropyrrolo[3,4-c]pyrrol-5-yl)-(2-fluoro-6-(2H-1,2,3-triazol-2-yl)phenyl)methanone. The compound is a hexahydropyrrolo[3,4-c]pyrrole derivative bearing a 4,6-dimethylpyrimidine at the 2-nitrogen and a 2-fluoro-6-(triazol-2-yl)benzoyl group at the 5-nitrogen, placing it within a structurally novel chemical class distinct from the diazepane scaffold of suvorexant and the pyridine-based scaffolds of lemborexant and daridorexant [2].

PubChem CID: 86278359.

1.2 Structural class and chemistry

Seltorexant belongs to the hexahydropyrrolo[3,4-c]pyrrole class of orexin receptor antagonists, a bicyclic pyrrolidine scaffold developed at Janssen Research and Development. The structural class is characterized by a fused bicyclic amine core that provides a rigid three-dimensional framework for receptor binding, with pendant heterocyclic substituents (the 4,6-dimethylpyrimidine and the 1,2,3-triazole-bearing fluorophenyl amide) conferring selectivity for OX2R over OX1R and other neuronal targets [1, 2].

Molecular formula: C₂₁H₂₂FN₇O (free base).

Molecular weight: 407.45 g/mol (free base).

Physical properties: The compound is supplied as a white to off-white crystalline solid. The hydrochloride salt form has been described in patent literature (WO2023163964A1) with characterization of multiple polymorphic solid-state forms suitable for pharmaceutical formulation [3]. The free base is the form used in the majority of research-grade preparations; the hydrochloride salt is the formulated clinical material.

Stereochemistry: The hexahydropyrrolo[3,4-c]pyrrole core contains two stereocenters at the 3a and 6a ring junction positions. The clinical candidate is supplied as the racemic mixture or as a defined stereoisomer depending on the synthetic route; investigators should confirm stereochemical identity by chiral analytical methods when stereoisomer-specific pharmacology is a study objective.

1.3 Synthesis

The original synthesis of seltorexant was described in the Bonaventure et al. (2015) report and in the associated Janssen patent literature (WO2011/050198) [1, 3]. The synthesis proceeds through two convergent branches. In the first branch, 2-fluoro-6-(1,2,3-triazol-2-yl)benzoic acid is prepared via copper-mediated coupling of 2-fluorobenzoic acid with 1,2,3-triazole in dioxane. In the second branch, the hexahydropyrrolo[3,4-c]pyrrole core is constructed by condensation of an appropriately protected pyrrolidine diamine precursor with 2-chloro-4,6-dimethylpyrimidine, followed by catalytic hydrogenation in the presence of acetic acid to yield the acetic acid salt of the deprotected amine. The two fragments are joined by conversion of the benzoic acid to the corresponding acid chloride, followed by amide coupling with the secondary amine of the pyrrolo[3,4-c]pyrrole to yield crude seltorexant. Purification is achieved by recrystallization, typically from ethanol or ethyl acetate, and the product is characterized by nuclear magnetic resonance spectroscopy, high-performance liquid chromatography, and mass spectrometry. The hydrochloride salt is prepared by treatment with stoichiometric hydrogen chloride and recrystallization. Industrial-scale synthesis optimizes the copper-mediated triazole coupling and the amide bond formation steps for yield and purity; the compound is manufactured at greater than 98 percent chemical purity for clinical supply [3].

2. Abstract

Seltorexant (JNJ-42847922, MIN-202) is a selective, high-affinity antagonist of the orexin-2 receptor (OX2R) and the first selective 2-SORA advanced through Phase 3 clinical development for major depressive disorder (MDD) with insomnia symptoms [1, 4]. The compound exhibits approximately 100-fold selectivity for OX2R over OX1R ($pK_i = 8.0$ for human OX2R) and negligible affinity for 50 other receptors, transporters, and ion channels, a pharmacological profile that positions it as a mechanistically distinct candidate relative to the dual orexin receptor antagonists (DORAs) suvorexant, lemborexant, and daridorexant, which are approved for primary insomnia but not for mood disorder indications [1, 5].

The orexin neuropeptide system, comprising orexin-A and orexin-B (also designated hypocretin-1 and hypocretin-2) and their two G-protein-coupled receptors OX1R and OX2R, is a principal regulator of wakefulness, arousal, stress reactivity, and hypothalamic-pituitary-adrenal (HPA) axis function. Dysregulation of orexin-ergic signaling has been implicated in the hyperarousal, sleep disruption, and HPA axis overactivation that characterize MDD with insomnia, and OX2R blockade represents a targeted approach to normalizing these pathophysiological circuits [6, 7].

The clinical development program has generated a substantial evidence base. The Phase 1b study in 47 MDD patients (Recourt et al. 2019) demonstrated significant antidepressant effects at 20 mg daily on the HDRS17 and HAM-D6 core symptom subscale [8]. The Phase 2b adaptive dose-finding study (Savitz et al. 2021) in 283 patients with inadequate SSRI or SNRI response identified 20 mg as the optimal adjunctive dose, with clinically meaningful improvements in depression (41.0 percent response rate versus 28.5 percent placebo), sleep quality, and insomnia severity, with greatest benefit in patients with baseline Insomnia Severity Index scores of 15 or above [9]. The pivotal Phase 3 MDD3001 trial met all primary and secondary endpoints (MADRS least-squares mean difference negative 2.6, $p = 0.007$), and the Phase 3 MDD3005 active-comparator trial demonstrated comparable efficacy to quetiapine extended-release with a substantially more favorable tolerability profile (somnolence 6 percent versus 24 percent; weight gain 0.5 kg versus 2.1 kg) [10, 11]. A monotherapy study published in *Molecular Psychiatry* (2024) confirmed antidepressant activity independent of concurrent SSRI or SNRI use [12].

Seltorexant is well tolerated, with headache, somnolence, and nausea as the most frequent adverse events at incidences comparable to placebo. No cataplexy, no significant abuse liability signals, and no serious treatment-emergent adverse events have been reported in the seltorexant arms of completed trials. The compound has not yet received regulatory approval in any jurisdiction and is under active Phase 3 development. This monograph reviews the complete pharmacological, pharmacokinetic, preclinical, and clinical evidence base and provides a structured comparative assessment against five orexin receptor antagonist alternatives.

3. Discovery and Development History

3.1 Origin

Seltorexant was synthesized at Janssen Research and Development (a Johnson and Johnson subsidiary) as part of a medicinal chemistry program exploring selective orexin-2 receptor antagonists for the treatment of insomnia and related neuropsychiatric conditions [1]. The program was motivated by the hypothesis that selective OX2R antagonism could promote sleep with fewer side effects than dual orexin receptor antagonism or GABA-ergic hypnotics, based on the observation that OX2R is the principal receptor subtype mediating the wake-promoting effects of orexin in the tuberomammillary nucleus and ventrolateral preoptic area, while OX1R mediates primarily reward, arousal, and autonomic functions through locus coeruleus projections [5, 6].

3.2 Preclinical characterization

The comprehensive preclinical characterization was reported by Bonaventure et al. in the Journal of Pharmacology and Experimental Therapeutics in 2015 [1]. This seminal report established the in vitro selectivity profile (pKi 8.0 and 8.1 for human and rat OX2R, respectively; approximately 100-fold selectivity over OX1R), confirmed blood-brain barrier penetration and in vivo OX2R occupancy by competitive radioligand binding in Sprague Dawley rats (oral 30 mg/kg producing 74.7 percent receptor occupancy at 60 minutes), and demonstrated dose-dependent NREM sleep promotion and stress-induced ACTH suppression in rodent models. The absence of effects in OX2R knockout mice confirmed target specificity. The report concluded that JNJ-42847922 was a suitable clinical candidate for insomnia and that the pharmacokinetic profile (rapid absorption, short half-life) was optimal for a bedtime sleep-promoting agent.

3.3 Licensing and partnership

In 2014, Janssen Pharmaceuticals entered a licensing agreement with Minerva Neurosciences for the co-development of seltorexant (designated MIN-202 under the Minerva agreement) for the treatment of insomnia and MDD. The partnership

combined Janssen's preclinical and formulation expertise with Minerva's clinical-stage neuropsychiatry development infrastructure. Subsequent clinical development has been conducted principally under Johnson and Johnson sponsorship with Minerva Neurosciences as a development partner [4].

3.4 Clinical development timeline

The clinical program advanced through a defined sequence: Phase 1 single ascending dose study in healthy volunteers (2013 to 2014; doses 1 to 80 mg) [1]; Phase 2 insomnia study in 27 patients (De Boer et al. 2018; 5 to 40 mg for 4 weeks) [13]; Phase 2 multiple-dose safety and tolerability study in healthy volunteers (Van der Ark et al. 2019) [14]; Phase 1b depression study in 47 MDD patients (Recourt et al. 2019; 20 mg daily for 10 to 28 days) [8]; Phase 2b adjunctive therapy adaptive dose-finding study in 283 MDD patients (Savitz et al. 2021; 10, 20, and 40 mg for 6 weeks) [9]; Phase 3 MDD3001 pivotal placebo-controlled trial (reported 2024; 20 mg for 43 days) [10]; Phase 3 MDD3005 active-comparator trial versus quetiapine extended-release (reported 2025; 20 mg for 26 weeks) [11]; and Phase 1b monotherapy study in 128 MDD patients (2024; 20 and 40 mg) [12]. Phase 3 trials for the adjunctive MDD indication are ongoing (NCT04532749, NCT04533529, NCT04513912, NCT06559306). Phase 2 development for insomnia and Alzheimer's disease is in progress [4].

3.5 Regulatory status

Seltorexant has not received regulatory approval in any jurisdiction as of the date of this monograph. No new drug application (NDA) or marketing authorization application (MAA) has been publicly disclosed. The compound remains an investigational agent. The regulatory trajectory is expected to depend on the results of the ongoing Phase 3 program and subsequent NDA submission to the United States Food and Drug Administration and the European Medicines Agency.

4. Mechanism of Action

Seltorexant is a selective orexin-2 receptor antagonist. Its principal molecular activity is competitive antagonism at the OX2R G-protein-coupled receptor, blocking the wake-promoting and stress-activating effects of endogenous orexin neuropeptides. The mechanism operates within the broader orexin neuromodulatory system, which regulates wakefulness, sleep-wake transitions, HPA axis function, autonomic tone, and mood [5, 6, 7].

4.1 The orexin system

The orexin (hypocretin) system comprises two neuropeptides, orexin-A and orexin-B, produced by a discrete population of approximately 50,000 to 80,000 neurons in the lateral hypothalamic area, the perifornical area, and the dorsomedial hypothalamus [5]. These neurons project extensively throughout the central nervous system, including to the locus coeruleus (noradrenergic wake-promoting), the tuberomammillary nucleus (histaminergic wake-promoting), the dorsal raphe (serotonergic), the ventral tegmental area (dopaminergic reward), the basal forebrain (cholinergic arousal), the amygdala (fear and anxiety), the bed nucleus of the stria terminalis (stress reactivity), and the paraventricular nucleus of the hypothalamus (HPA axis regulation) [6, 7].

The two orexin receptors are G-protein-coupled receptors of the rhodopsin family. OX1R couples predominantly to Gq/11 and signals through phospholipase C, inositol trisphosphate, and intracellular calcium mobilization. OX2R couples to both Gq/11 and Gi/o, providing a broader signaling repertoire that includes both calcium mobilization and adenylyl cyclase inhibition [5]. OX1R has approximately equal affinity for orexin-A and orexin-B, whereas OX2R has approximately 10-fold higher affinity for orexin-B over orexin-A, establishing orexin-B as the principal endogenous OX2R agonist [5].

4.2 OX2R antagonism and sleep promotion

The sleep-promoting effect of OX2R antagonism derives from the selective blockade of orexin signaling at the tuberomammillary nucleus and ventrolateral preoptic area, the principal brain regions where OX2R activation maintains wakefulness by sustaining histaminergic and GABAergic tone, respectively [1, 5]. Blockade of OX2R at these sites reduces the wake-promoting drive during the biological sleep period and facilitates the transition to NREM sleep. Preclinical evidence in rats demonstrated that seltorexant produces dose-dependent reductions in NREM sleep latency and increases in NREM sleep duration at oral doses of 3 to 30 mg/kg, with effects more pronounced during the dark (active) phase than the light (rest) phase [1]. The compound did not significantly alter REM sleep duration or REM sleep latency at tested doses, suggesting selective modulation of the NREM sleep initiation pathway rather than global sleep architecture disruption [1, 15].

The selectivity for OX2R over OX1R is a defining pharmacological characteristic. OX1R is more prominently expressed in the locus coeruleus and the ventral tegmental area, where it mediates arousal-related autonomic activation and reward-associated dopamine release. By sparing OX1R, seltorexant avoids the theoretical concern of reward pathway modulation and maintains a cleaner separation between sleep promotion and arousal or reward circuit effects [1, 5]. This selectivity was confirmed by the absence of seltorexant effects on extracellular dopamine release in rat nucleus accumbens at sleep-promoting doses (30 mg/kg) and by the absence of conditioned place preference in mice [1].

4.3 HPA axis modulation and antidepressant mechanism

The antidepressant mechanism of seltorexant is hypothesized to operate through normalization of orexinergic hyperarousal and HPA axis overactivation, two pathophysiological features consistently observed in MDD with insomnia [6, 7, 8]. Orexin neurons project to the paraventricular nucleus of the hypothalamus, where OX2R activation stimulates corticotropin-releasing hormone (CRH) release and downstream ACTH and cortisol secretion. In MDD, elevated evening and nocturnal cortisol, disrupted cortisol circadian rhythm, and hyperactivation of the HPA axis are reproducible findings that correlate with insomnia severity and treatment resistance [6, 7].

Seltorexant at 30 mg/kg in rats abolished the stress-induced increase in ACTH levels in an elevated platform stress test and inhibited stress-induced c-Fos expression in the paraventricular nucleus, demonstrating direct suppression of the stress-activated HPA axis circuit through OX2R blockade [1]. Notably, the dual OX1R/OX2R antagonist SB-649868 only partially attenuated the same ACTH response, suggesting that OX2R is the predominant receptor subtype mediating stress-induced HPA axis activation and that selective OX2R antagonism may be more effective than dual antagonism for this specific mechanism [1, 15].

The clinical translation of this mechanism is supported by the Recourt et al. (2019) observation that seltorexant produced antidepressant effects on core depressive symptoms (HAM-D6 subscale: inner tension, pessimistic thoughts, inability to feel, lassitude, concentration difficulties) that are distinct from and independent of sleep improvement [8]. The improvement in rumination scores correlated with antidepressant response ($R^2 = 0.199$, $p < 0.05$), supporting the hypothesis that reduction of nocturnal hyperarousal and HPA axis activation contributes to the antidepressant mechanism beyond simple sleep normalization [8].

4.4 Selectivity profile

Seltorexant was tested at 1 micromolar concentration against a panel of 50 receptors, ion channels, and transporters and showed no significant affinity for any target other than OX2R [1]. Specific negative findings include absence of binding to GABA-A receptor subtypes, benzodiazepine binding sites, dopamine D1 through D5 receptors, serotonin 5-HT1A through 5-HT7 receptor subtypes, noradrenergic alpha-1, alpha-2, and beta receptors, histamine H1 through H3 receptors, muscarinic M1 through M5 receptors, opioid mu, delta, and kappa receptors, and voltage-gated sodium, potassium, and calcium channels. This clean selectivity profile underlies the favorable tolerability observed in clinical trials and distinguishes seltorexant from the atypical antipsychotics (quetiapine, olanzapine) used off-label for insomnia in MDD, which have substantial off-target receptor binding at histamine, serotonin, dopamine, and adrenergic receptors [1, 9].

5. Pharmacokinetics and Routes of Administration

5.1 Absorption

Seltorexant is rapidly absorbed following oral administration. The median time to peak plasma concentration (T_{max}) ranges from 0.3 to 1.5 hours across dose levels, with the majority of studies reporting a mean T_{max} of 0.33 to 0.5 hours [1, 14]. This rapid absorption is one of the compound's distinguishing pharmacokinetic features and supports the clinical dosing paradigm of bedtime administration for rapid sleep onset facilitation.

Single ascending dose pharmacokinetic data in healthy male volunteers demonstrated the following parameters [1, 15]: 10 mg: C_{max} 309 plus or minus 74 ng/mL; AUC-infinity 802 plus or minus 275 ng times h/mL. 20 mg: C_{max} 556 plus or minus 104 ng/mL; AUC-infinity 1616 plus or minus 607 ng times h/mL. 40 mg: C_{max} 743 plus or minus 149 ng/mL; AUC-infinity 1807 plus or minus 533 ng times h/mL. 80 mg: C_{max} 1208 plus or minus 291 ng/mL; AUC-infinity 3655 plus or minus 1064 ng times h/mL.

Dose-proportional increases in C_{max} were observed across the 10 to 80 mg range, with less-than-dose-proportional increases in AUC at higher doses, suggesting some saturation of absorption or increased first-pass metabolism at higher doses [1, 15].

5.2 Distribution

Seltorexant distributes into the central nervous system following oral administration. Blood-brain barrier penetration was confirmed in vivo by competitive radioligand binding in Sprague Dawley rats, where oral administration at 30 mg/kg inhibited binding of a selective OX2R radioligand to the rat cortex [1]. Positron emission tomography (PET) imaging studies confirmed exceptional binding specificity for OX2R and suitable brain penetration [15]. The highest OX2R occupancy by seltorexant (74.7 percent) was observed 60 minutes after oral administration of 30 mg/kg in rats, declining to approximately 40 percent at 4 hours and returning to baseline at

24 hours [1, 15]. The compound exhibits relatively high free fractions as measured by protein binding in rats and humans, supporting efficient distribution to target tissues [15]. The compound is a P-glycoprotein substrate based on the observation that cyclosporin pretreatment increased brain uptake in preclinical studies [15].

5.3 Metabolism

Seltorexant is metabolized predominantly by cytochrome P450 3A4 (CYP3A4) in the liver [4, 15]. The metabolic pathway produces inactive hydroxylated and oxidized metabolites. Unlike the CYP2D6-dependent metabolism of tropisetron and some other neuropsychiatric agents, the CYP3A4 dependence of seltorexant does not produce a clinically significant polymorphic phenotype, since CYP3A4 does not exhibit the loss-of-function allele distribution characteristic of CYP2D6. However, the CYP3A4 dependence creates the potential for drug-drug interactions with strong CYP3A4 inhibitors (ketoconazole, itraconazole, ritonavir, clarithromycin) and strong CYP3A4 inducers (rifampin, carbamazepine, phenytoin, St. John's wort), which should be considered in concurrent prescribing and research protocols [15].

5.4 Elimination

The elimination half-life of seltorexant is approximately 2 to 3 hours, placing it among the shortest-acting orexin receptor antagonists in clinical development or on the market [1, 14, 15]. For comparison, the elimination half-lives of the approved DORAs are approximately 12 hours for suvorexant, 17 to 19 hours for lemborexant, and approximately 8 hours for daridorexant [15, 16]. The short half-life of seltorexant is a deliberate design feature intended to minimize next-day residual sedation and to support a pharmacokinetic profile in which receptor occupancy is high during the first hours of the biological sleep period and declines to negligible levels by morning.

Plasma concentration follows an apparently monophasic decline after the absorption phase, consistent with rapid distribution equilibrium and predominantly hepatic elimination [1]. No residual effects of the medication were observed 4 hours after daytime administration in Phase 1 studies, confirming the absence of clinically meaningful next-day impairment at therapeutic doses [1, 14].

5.5 Routes of administration

The compound is administered orally as a single daily dose at bedtime. All clinical trials to date have used the oral route. The clinical formulation is a capsule or tablet containing seltorexant hydrochloride. No parenteral formulations have been described in the clinical literature. Research-grade material is supplied as the free base or hydrochloride salt for reconstitution in appropriate vehicles for in vitro and in vivo studies.

5.6 Special populations

Elderly patients (65 years and older) were included in the Phase 3 MDD3001 and MDD3005 trials, and the compound was well tolerated in this population [10, 11]. Detailed age-stratified pharmacokinetic data have not been published in peer-reviewed form. Hepatic impairment data have not been reported; given the CYP3A4-dependent metabolism, dose adjustment in moderate-to-severe hepatic impairment may be appropriate. Renal impairment data have not been reported but are expected to be of limited relevance given the predominantly hepatic elimination. Women of childbearing potential were underrepresented in early-phase trials (less than 10 percent of the Phase 2b population), though broader enrollment was implemented in Phase 3 studies [9, 10].

6. Preclinical Pharmacology

6.1 In vitro receptor pharmacology

Seltorexant is a high-affinity antagonist of the human orexin-2 receptor with a pK_i of 8.0 (K_i approximately 10 nM). Selectivity over OX1R is approximately 80- to 100-fold, as determined by intracellular calcium mobilization assays in cells expressing human or rat OX1R and OX2R [1]. In a comprehensive selectivity panel of 50 receptors, ion channels, and transporters at 1 micromolar concentration, seltorexant showed no significant affinity for any non-orexin target [1].

Functional antagonism was confirmed by dose-dependent inhibition of orexin-B-stimulated intracellular calcium release in CHO cells stably expressing human OX2R, with IC_{50} values consistent with the binding affinity. The compound acts as a competitive (surmountable) antagonist at the orthosteric orexin binding site, distinguishing it from non-competitive or allosteric modulators [1].

6.2 Sleep pharmacology in rodent models

Oral administration of seltorexant to Sprague Dawley rats produced dose-dependent increases in NREM sleep time and reductions in NREM sleep onset latency beginning at 3 mg/kg, with maximal effects at 30 mg/kg [1]. The sleep-promoting effects were more pronounced during the dark (active) phase than the light (rest) phase, consistent with antagonism of the endogenous orexin wake-promoting signal, which is highest during the active period. NREM sleep time continued to increase across the 3 to 30 mg/kg dose range without plateau [1].

REM sleep was not significantly affected at the tested doses, a finding that distinguishes seltorexant from the DORAs, which tend to increase REM sleep proportion as well as total sleep time [1, 16]. The selective NREM promotion is consistent with the predominant role of OX2R in the histaminergic wake-promoting circuit of the tuberomammillary nucleus.

Sleep-promoting effects were maintained upon 7-day repeated dosing without evidence of tolerance or rebound wakefulness upon drug discontinuation [1]. This finding supports chronic use paradigms and is consistent with the absence of

GABA-ergic neuroadaptation that limits the long-term utility of benzodiazepines and Z-drugs.

6.3 OX2R knockout confirmation

The specificity of seltorexant for OX2R was confirmed by the absence of sleep-promoting effects in OX2R knockout mice [1]. This genetic validation is the most stringent confirmation of target specificity available in preclinical pharmacology and distinguishes seltorexant from agents whose sleep-promoting effects might be attributable to off-target activity at GABA-A receptors, histamine H1 receptors, or other sedative targets.

6.4 HPA axis and stress pharmacology

Seltorexant at 30 mg/kg abolished the stress-induced elevation of plasma ACTH in the elevated platform stress test in rats, while the dual OX1R/OX2R antagonist SB-649868 only partially attenuated the same response [1]. This finding establishes OX2R as the predominant receptor subtype mediating stress-induced HPA axis activation and supports the mechanistic rationale for OX2R-selective antagonism in depression, where HPA axis overactivation is a consistent pathophysiological finding.

Additionally, seltorexant inhibited stress-induced c-Fos expression in the paraventricular nucleus of the hypothalamus, the central integrating node for CRH release and downstream ACTH and cortisol secretion [1]. The suppression of paraventricular nucleus activation provides a neuroanatomical mechanism for the observed ACTH reduction and for the hypothesized antidepressant activity.

6.5 Abuse liability and reward pharmacology

Seltorexant did not produce conditioned place preference in mice at doses up to 30 mg/kg following subchronic conditioning, indicating absence of rewarding properties [1]. The compound did not increase extracellular dopamine release in the nucleus accumbens at 30 mg/kg (the maximally sleep-promoting dose), in contrast to zolpidem (10 mg/kg) and amphetamine (2 mg/kg), which both produced significant dopamine elevations [1]. These findings support a favorable abuse liability profile and distinguish seltorexant from GABA-ergic hypnotics, which carry Schedule IV controlled substance designations and clinical abuse potential.

6.6 Motor coordination

Seltorexant had no effect on motor coordination in the rotarod test at sleep-promoting doses and did not potentiate the ataxic effects of alcohol [1]. This finding supports the safety profile for evening dosing and distinguishes the compound from benzodiazepines and Z-drugs, which impair motor coordination and potentiate alcohol-induced ataxia.

7. Clinical Evidence Base

7.1 Phase 1 single ascending dose study (Bonaventure et al. 2015)

The first-in-human study evaluated single oral doses of 1 to 80 mg of seltorexant in healthy male volunteers [1]. The compound demonstrated a suitable pharmacokinetic profile characterized by rapid absorption (T_{max} 0.33 to 0.5 hours), short elimination half-life (approximately 2 hours), and dose-proportional increases in plasma exposure. Somnolence was the principal pharmacodynamic effect, dose-dependent, and resolved within 4 hours of daytime administration. No serious adverse events, clinically significant vital sign changes, or electrocardiographic abnormalities were observed at any dose level. The study supported advancement to efficacy studies in patient populations.

7.2 Phase 2 insomnia study (De Boer et al. 2018)

A randomized, double-blind, placebo-controlled study in 27 patients with primary insomnia evaluated seltorexant at 5, 10, 20, and 40 mg daily for 4 weeks [13]. Polysomnographic outcomes demonstrated significant improvements in sleep efficiency (5.8 percent and 7.9 percent improvement at days 1/2, p less than or equal to 0.001), total sleep time (increases of 27.7 and 37.9 minutes), and latency to persistent sleep (reductions of 18.8 and 29.9 minutes). Headache and somnolence were the most common adverse events. The study confirmed the sleep-promoting activity observed in preclinical models and established the dose range for subsequent depression trials.

7.3 Phase 1b depression study (Recourt et al. 2019)

An exploratory, double-blind, multicentre Phase 1b trial randomized 47 patients with MDD (IDS-C30 score 30 or above) in a 2:1:1 ratio to seltorexant 20 mg daily at bedtime, diphenhydramine 25 mg (negative control), or placebo for 10 days (women of childbearing potential) or 28 days (others) [8]. The study was conducted across sites in the Netherlands, Belgium, and Germany.

Primary depression outcomes: Post-hoc ANCOVA analysis demonstrated a statistically significant improvement in adjusted HDRS17 score with seltorexant versus placebo (least-squares mean difference negative 2.2, 95 percent confidence interval negative 4.35 to negative 0.05, $F = 4.37$, $p < 0.05$). The HAM-D6 core symptom subscale showed a larger and more statistically robust effect (difference negative 2.5, 95 percent confidence interval negative 4.14 to negative 0.80, $F = 9.11$, $p < 0.01$) [8]. Mean reductions from baseline in HDRS17 were negative 5.5 (standard deviation 3.86) for seltorexant versus negative 3.6 (standard deviation 4.03) for placebo.

Sleep outcomes: No significant between-group differences were observed on polysomnographic parameters (total sleep time, wake after sleep onset, latency to persistent sleep). However, electroencephalographic power spectral analysis revealed that seltorexant increased total power and posterior delta power and decreased theta, alpha, and beta power during stage 2 sleep ($p < 0.10$), consistent with deeper NREM sleep physiology [8].

Rumination: Improvement in HDRS17 correlated significantly with reduction in rumination in the seltorexant group ($R\text{-squared} = 0.199$, $p < 0.05$), supporting the hypothesis that orexinergic hyperarousal reduction contributes to antidepressant efficacy through cognitive-emotional mechanisms [8].

Tolerability: The most common adverse events were somnolence, fatigue, headache, dizziness, abdominal discomfort, and nightmares, all mild to moderate and transient. No serious adverse events were reported in the seltorexant arm. One suicide event occurred in the diphenhydramine arm after study completion [8].

7.4 Phase 2b adjunctive therapy study (Savitz et al. 2021)

A Phase 2b, randomized, double-blind, placebo-controlled, adaptive dose-finding trial was conducted across 81 sites in 7 countries (Bulgaria, Finland, Germany, Japan, Russia, Ukraine, United States) from August 2017 to January 2019 [9]. A total of 283 patients with MDD and inadequate response to 1 to 3 prior antidepressants were randomized to placebo, seltorexant 10 mg, 20 mg, or 40 mg administered once daily at bedtime as adjunctive therapy to ongoing SSRI or SNRI.

Patient demographics: Mean age 49.1 years, 53.7 percent women, 78.8 percent White. Mean baseline MADRS score 33.7, mean CGI-S 4.8. Insomnia Severity Index 15 or above in 57.6 percent. Current SSRI use in 68.9 percent [9].

Primary endpoint: The MCP-Mod dose-response analysis did not reach statistical significance ($p = 0.08$ against a threshold of $p = 0.05$). The sigmoid Emax model showed best fit. MMRM analysis demonstrated the greatest improvement with seltorexant 20 mg: least-squares mean difference from placebo of negative 4.5 at week 3 (90 percent confidence interval negative 6.96 to negative 2.07, $p = 0.003$) and negative 3.1 at week 6 (90 percent confidence interval negative 6.13 to negative 0.16, $p = 0.083$) [9].

Response and remission rates at week 6: Response (50 percent or greater MADRS reduction) was 41.0 percent for seltorexant 20 mg versus 28.5 percent for placebo. Remission (MADRS 12 or below) was 29.5 percent versus 19.0 percent [9].

Insomnia subgroup analysis: Patients with baseline ISI 15 or above showed a greater treatment effect with seltorexant 20 mg (least-squares mean difference negative 4.9, 90 percent confidence interval negative 8.98 to negative 0.80) compared to patients with ISI below 15 (difference negative 0.7, 90 percent confidence interval negative 5.16 to 3.76), identifying insomnia severity as a potential enrichment biomarker [9].

Sleep outcomes: Seltorexant 20 mg produced significant improvements in ISI total score (difference negative 2.3, 90 percent confidence interval negative 3.90 to negative 0.67) and PROMIS Sleep Disturbance (difference negative 4.4, 90 percent confidence interval negative 6.82 to negative 2.04) [9].

Safety: Treatment-emergent adverse events occurred in 37.7 percent of seltorexant-treated patients versus 40.9 percent of placebo. Most common adverse events were headache (6.2 percent versus 6.6 percent placebo), somnolence (6.2 percent versus 5.1 percent), and nausea (5.5 percent versus 2.9 percent). No deaths or serious TEAEs were reported in any seltorexant group. No clinically significant suicidal ideation increase or suicidal behavior was reported. No cataplexy was observed. Discontinuation due to adverse events: 4.1 percent seltorexant versus 1.5 percent placebo [9].

Study completion rate: 87.5 percent (251 of 283 patients) [9].

7.5 Phase 3 MDD3001 pivotal trial (2024)

The Phase 3 MDD3001 study was a randomized, double-blind, multicenter, placebo-controlled trial evaluating seltorexant 20 mg administered once daily at bedtime as adjunctive therapy to SSRI or SNRI in adult and elderly patients with MDD and in-

somnia symptoms who had demonstrated inadequate response to antidepressant monotherapy [10].

The study met its primary endpoint: the least-squares mean difference in MADRS total score between seltorexant and placebo at day 43 was negative 2.6 ($p = 0.007$). Key secondary endpoints were also met, including MADRS without sleep, onset of insomnia, and appetite/weight items (MADRS-WOSI, difference negative 2.0, $p = 0.023$) and PROMIS Sleep Disturbance T-score (difference negative 3.7, $p < 0.001$) [10].

Tolerability: Similar rates of common adverse events were observed in both treatment arms, consistent with the safety profile established in earlier trials [10].

7.6 Phase 3 MDD3005 active comparator trial (2025)

The Phase 3 MDD3005 study was a randomized, double-blind, parallel-group study comparing seltorexant 20 mg to quetiapine extended-release as adjunctive therapy to SSRI or SNRI in adult and elderly patients with MDD and insomnia symptoms over 26 weeks [11].

Efficacy: The response rate (50 percent or greater MADRS improvement) was 57.4 percent for seltorexant versus 53.4 percent for quetiapine XR. This difference was numerically in favor of seltorexant but did not reach statistical significance for the primary endpoint [11].

Tolerability: Seltorexant demonstrated a substantially more favorable tolerability profile than quetiapine XR. Somnolence incidence was 6 percent for seltorexant versus 24 percent for quetiapine XR (a four-fold difference). Weight gain averaged 0.5 kg for seltorexant versus 2.1 kg for quetiapine XR over 26 weeks. More patients completed the 26-week study in the seltorexant arm than in the quetiapine XR arm, reflecting the better tolerability [11].

7.7 Monotherapy study (2024)

A Phase 1b placebo-controlled, placebo lead-in, randomized, double-blind study evaluated seltorexant 20 mg and 40 mg as monotherapy (without concurrent SSRI or SNRI) in 128 patients with MDD [12]. The enriched intent-to-treat analysis (lead-in placebo non-responders, $n = 86$) demonstrated mean changes from baseline in HDRS17 score at week 5 of negative 7.0 (standard deviation 5.04) for seltorexant 20

mg and negative 5.5 (standard deviation 4.34) for seltorexant 40 mg. The study confirmed that seltorexant has intrinsic antidepressant activity independent of adjunctive SSRI or SNRI use, supporting the hypothesis that OX2R antagonism addresses a primary pathophysiological mechanism in MDD rather than simply augmenting monoaminergic antidepressant effects [12].

7.8 Alzheimer's disease

Seltorexant is under Phase 2 investigation for Alzheimer's disease, based on the role of sleep disruption and orexinergic dysregulation in amyloid accumulation and cognitive decline [4]. Clinical results in this indication have not been reported.

8. Sourcing and Quality Verification

Research-grade seltorexant is available from multiple chemical and pharmaceutical research suppliers, including MedChemExpress, Cayman Chemical, Selleckchem, TargetMol, GlpBio, and others, at greater than 98 percent purity by HPLC [17]. Supply is in milligram to gram quantities as the free base or hydrochloride salt. Pricing is moderate to high for a non-generic investigational compound, typically in the range of \$100 to \$500 per 10 to 50 milligrams of research-grade material at the time of monograph preparation.

Pharmaceutical-grade seltorexant is not commercially available, as the compound has not received regulatory approval. Clinical-trial material is manufactured by Janssen Pharmaceuticals under Good Manufacturing Practice (GMP) conditions and is available only through enrollment in sponsored clinical trials.

Investigators should confirm compound identity and purity on every research-grade lot through:

- High-performance liquid chromatography area-percent purity, ideally greater than 98 percent.
- Mass spectrometry confirmation of molecular weight (408.45 for the protonated free base $[M+H]^+$, calculated from $C_{21}H_{22}FN_7O + H$).
- Nuclear magnetic resonance spectroscopy confirmation of structure, particularly the hexahydropyrrolo[3,4-c]pyrrole core protons, the dimethylpyrimidine methyl singlets, and the triazole aromatic protons.
- Karl Fischer or loss-on-drying analysis for residual water content.
- Residual solvent analysis by gas chromatography if the compound was recrystallized from organic solvents.

Third-party analytical laboratories (Janoshik Analytical, Anabolic Lab, others) provide independent verification of vendor certificates of analysis. As seltorexant is an investigational compound without a generic market, the risk of counterfeit material is low; however, lot-to-lot variability in research-grade preparations is possible and on-receipt analytical confirmation is appropriate for any dose-response or mechanism-of-action study requiring precision.

9. Reconstitution and Handling

Seltorexant free base is a crystalline solid with moderate aqueous solubility. For in vitro research applications, stock solutions are typically prepared in dimethyl sulfoxide (DMSO) at concentrations of 10 to 50 mM and stored at negative 20 degrees Celsius. Working dilutions are prepared in the appropriate assay buffer or cell culture medium immediately before use. The final DMSO concentration in biological assays should not exceed 0.1 to 0.5 percent (volume/volume) to avoid solvent-related cytotoxicity or receptor interference.

For in vivo rodent studies, the compound has been administered by oral gavage in vehicles including 20 percent hydroxypropyl-beta-cyclodextrin in water, methylcellulose suspensions, and polyethylene glycol-based vehicles [1]. The compound is stable in solution at refrigerated conditions (2 to 8 degrees Celsius) for research-relevant timeframes; investigators should verify stability under their specific vehicle and storage conditions.

The hydrochloride salt form has improved aqueous solubility relative to the free base. Solid-state polymorphic forms have been characterized in patent literature (WO2023163964A1), and investigators acquiring the hydrochloride salt should be aware that different polymorphic forms may have different dissolution rates and apparent solubility [3].

Storage of the solid material should be at negative 20 degrees Celsius for long-term storage (greater than 6 months) or at 2 to 8 degrees Celsius for short-term storage (less than 6 months), in sealed containers protected from moisture. The compound is not known to be light-sensitive, but light protection is reasonable practice for long-term storage.

10. Stack Interactions and Combinations

Seltorexant interacts with several drug classes through its CYP3A4-dependent metabolism and its orexinergic pharmacology. Investigators conducting research with seltorexant, particularly in chronic dosing regimens or in combination with other compounds, should consider the following:

CYP3A4 inhibitors: Strong inhibitors (ketoconazole, itraconazole, ritonavir, clarithromycin, grapefruit juice) are expected to substantially increase seltorexant exposure by inhibiting first-pass and systemic metabolism. Suvorexant labeling documents a 2.79-fold increase in AUC with ketoconazole co-administration, and a similar magnitude of interaction is plausible for seltorexant given the shared CYP3A4 dependence [15, 16]. Dose reduction or avoidance of concurrent strong CYP3A4 inhibitors is appropriate.

CYP3A4 inducers: Strong inducers (rifampin, carbamazepine, phenytoin, phenobarbital, St. John's wort) are expected to substantially reduce seltorexant exposure by increasing hepatic CYP3A4 activity. Concurrent use may compromise the efficacy of seltorexant, and alternative medications should be considered.

SSRI and SNRI antidepressants: Seltorexant was developed as an adjunctive therapy to SSRIs and SNRIs, and the Phase 2b and Phase 3 clinical trials were conducted with ongoing SSRI or SNRI treatment. No pharmacokinetic interaction between seltorexant and SSRIs or SNRIs has been reported. The combination is the intended clinical use and has demonstrated favorable efficacy and tolerability [9, 10].

Other orexin receptor antagonists: Concurrent use with DORAs (suvorexant, lemborexant, daridorexant) is pharmacologically redundant and may produce excessive orexin receptor blockade, potentially increasing the risk of somnolence, sleep paralysis, and cataplexy-like events. The combination has not been studied and is not recommended.

Benzodiazepines and Z-drugs: Concurrent use with GABA-ergic hypnotics (zolpidem, zopiclone, eszopiclone, benzodiazepines) may produce additive sedation. The combination should be used with caution, particularly in elderly patients or those

with respiratory compromise. Seltorexant's favorable abuse and tolerance profile relative to GABA-ergic agents suggests that it may be suitable as a replacement rather than an addition to these compounds.

Alcohol: Although seltorexant did not potentiate alcohol-induced ataxia in the preclinical rotarod test [1], clinical caution is appropriate with concurrent alcohol use owing to the additive sedative potential.

Atypical antipsychotics: The Phase 3 MDD3005 trial demonstrated that seltorexant 20 mg had comparable efficacy to quetiapine XR with substantially fewer adverse events [11]. Concurrent use of seltorexant with quetiapine or other sedating atypical antipsychotics may produce additive somnolence and is pharmacologically redundant for the sleep-promoting component. Investigators transitioning patients from quetiapine to seltorexant should consider the metabolic and weight implications of quetiapine withdrawal.

P-glycoprotein inhibitors: Seltorexant is a P-glycoprotein substrate based on preclinical data showing increased brain uptake with cyclosporin [15]. Concurrent P-glycoprotein inhibitors (cyclosporin, verapamil, quinidine) may increase central nervous system exposure and pharmacodynamic effects.

11. Adverse Events and Safety

11.1 Common adverse events

The principal adverse events across the clinical program are [8, 9, 10, 11]:

- Headache (6.2 percent, similar to placebo at 6.6 percent)
- Somnolence (6.2 percent overall; 9.8 percent at 20 mg in Phase 2b; 6 percent in Phase 3)
- Nausea (5.5 percent versus 2.9 percent placebo)
- Fatigue (mild, transient)
- Dizziness (mild, transient)
- Abdominal discomfort (mild, transient)

These adverse events are predominantly mild to moderate in intensity and transient. The overall incidence of treatment-emergent adverse events with seltorexant (37.7 percent in Phase 2b) is comparable to or lower than placebo (40.9 percent), a finding that is unusual for psychotropic agents and reflects the clean selectivity profile [9].

11.2 Adverse events of special interest

Orexin receptor antagonism carries theoretical risks related to narcolepsy-like phenomena (cataplexy, sleep paralysis, hypnagogic hallucinations) and abnormal sleep-related behaviors. The following events of special interest were monitored [9]:

- Sleep paralysis: 1.4 percent seltorexant versus 0.7 percent placebo
- Abnormal dreams: 2.7 percent versus 0.7 percent
- Nightmares: 1.4 percent versus 0 percent
- Cataplexy: No cases reported in any seltorexant trial

No dose-response relationship was observed for these special interest events across the 10, 20, and 40 mg dose range [9]. The low incidence of sleep paralysis and the absence of cataplexy are reassuring findings that support the hypothesis that selec-

tive OX2R antagonism carries a lower risk of narcolepsy-spectrum events than dual OX1R/OX2R antagonism.

11.3 Serious adverse events

No deaths or serious treatment-emergent adverse events have been reported in any seltorexant treatment group across the completed clinical program [8, 9, 10, 11]. One suicide event occurred in the diphenhydramine control arm of the Phase 1b study after study completion; no suicidal behavior events occurred in any seltorexant arm [8]. No clinically significant increases in suicidal ideation were observed across treatment groups in any study [9].

11.4 Cardiovascular and metabolic safety

No consistent dose-related changes in mean vital signs (heart rate, blood pressure) or mean electrocardiographic parameters were observed with seltorexant treatment [9]. No genotoxicity was demonstrated in preclinical studies [15]. Weight gain with seltorexant was minimal (0.5 kg over 26 weeks) compared to quetiapine XR (2.1 kg), establishing a favorable metabolic safety profile for chronic use [11].

11.5 Abuse liability

Preclinical studies demonstrated absence of conditioned place preference and absence of nucleus accumbens dopamine release at sleep-promoting doses [1]. A human abuse liability study reported that seltorexant and lemborexant showed comparable drug-liking effects to zolpidem and suvorexant in recreational sedative users, warranting monitoring in addiction-prone populations [15]. However, the absence of GABA-ergic mechanisms, the short duration of action, and the absence of dopaminergic reward activation support a more favorable abuse liability profile than benzodiazepines and Z-drugs.

11.6 Comparative safety

A 2022 meta-analysis concluded that seltorexant had fewer side effects than benzodiazepines, eszopiclone, zolpidem, and zopiclone across pooled clinical data [15]. The Phase 3 MDD3005 head-to-head comparison with quetiapine XR demonstrated substantially fewer adverse events with seltorexant, including four-fold lower somnolence, four-fold lower weight gain, and higher study completion rates [11].

12. Comparable Compounds Assessment

This section presents a structured comparative assessment of five orexin receptor antagonist candidates against seltorexant, evaluated against five competency standards: novelty, effect size, promising potential (current clinical state and trajectory), side-effect profile (clinical or preclinical), and overall validation. The five candidates were selected as the principal orexin receptor ligands with substantive clinical pharmacology programs in sleep and mood applications, with priority on those that have produced material clinical evidence and on those that share seltorexant's clinical positioning.

12.1 Suvorexant (Belsomra, MK-4305)

Mechanism: Dual orexin receptor antagonist (DORA) with approximately equal affinity for OX1R (Ki 0.55 nM) and OX2R (Ki 0.35 nM) [16]. The dual mechanism blocks both the OX2R-mediated wake-promoting circuit and the OX1R-mediated arousal and reward circuits.

Development trajectory: Merck developed suvorexant as the first orexin receptor antagonist to receive regulatory approval. The compound was approved by the FDA in August 2014 for the treatment of insomnia characterized by difficulties with sleep onset and sleep maintenance. Multiple Phase 3 trials demonstrated significant improvements in polysomnographic endpoints (latency to persistent sleep, wake after sleep onset, total sleep time) in adult and elderly insomnia patients [16].

Novelty: Moderate at the time of approval (first-in-class DORA), now low. The mechanism has been validated by three subsequent DORA approvals.

Effect size: Moderate for insomnia endpoints. Not studied in MDD as a primary indication. The long half-life (12 hours) limits utility in depression paradigms requiring bedtime-only receptor occupancy.

Promising potential: Low for MDD. The compound is established for primary insomnia but has not been advanced for mood disorder indications. The long half-life and dual receptor mechanism are pharmacokinetic and pharmacological limita-

tions for the MDD application where selective OX2R antagonism and short duration appear to be therapeutic advantages.

Side-effect profile: The most common adverse events are somnolence (7 to 12 percent) and headache. Sleep paralysis and cataplexy-like events have been reported at low incidence. The compound carries a Schedule IV controlled substance designation based on abuse potential studies [16]. Next-day impairment is a labeled concern at the 20 mg dose, attributable to the 12-hour half-life.

Overall validation: High for insomnia. Low for MDD.

Comparison to seltorexant: Suvorexant and seltorexant share the orexin receptor antagonist class but differ fundamentally in selectivity (dual versus OX2R-selective), pharmacokinetics (12-hour versus 2-hour half-life), indication (insomnia versus MDD with insomnia), and regulatory status (approved versus investigational). Seltorexant's short half-life, OX2R selectivity, and demonstrated antidepressant efficacy distinguish it as a mechanistically different candidate optimized for a different therapeutic goal.

12.2 Lemborexant (Dayvigo, E2006)

Mechanism: Dual orexin receptor antagonist with preferential OX2R binding. Binding affinity is higher for OX2R than OX1R, though both receptors are antagonized at clinical doses. The rapid receptor dissociation kinetics of lemborexant are a distinguishing pharmacological feature [16].

Development trajectory: Eisai developed lemborexant through Phase 3 for insomnia. The compound was approved by the FDA in December 2019 for the treatment of insomnia at 5 mg and 10 mg doses [16]. Phase 3 trials (SUNRISE-1, SUNRISE-2) demonstrated significant improvements in polysomnographic and patient-reported sleep endpoints in adult and elderly insomnia patients.

Novelty: Low. The DORA mechanism is established. The preferential OX2R binding is a pharmacological refinement but does not constitute a novel mechanism.

Effect size: Moderate to high for insomnia. A meta-analysis found lemborexant to be the most effective of three DORAs on 3 of 4 polysomnographic outcomes (total sleep time, latency to persistent sleep, sleep efficiency) [16]. Not studied in MDD.

Promising potential: Low for MDD. The compound is established for insomnia. The long effective half-life (17 to 19 hours) makes it unsuitable for an MDD paradigm requiring short-duration bedtime dosing.

Side-effect profile: Common adverse events include somnolence (5 to 10 percent), headache, and abnormal dreams. The long half-life contributes to next-day residual sedation at higher doses. No cataplexy reported in registration trials [16].

Overall validation: High for insomnia. Low for MDD.

Comparison to seltorexant: Lemborexant shares OX2R antagonism but with less selectivity, slower dissociation, and a much longer half-life. Seltorexant's clean OX2R selectivity, 2-hour half-life, and demonstrated MDD efficacy position it for a different clinical niche (adjunctive MDD with insomnia) than lemborexant (primary insomnia).

12.3 Daridorexant (Quviviq, ACT-541468)

Mechanism: Dual orexin receptor antagonist with balanced OX1R and OX2R affinity. Developed by Idorsia (formerly Actelion, now Johnson and Johnson following acquisition) [16]. Half-life of approximately 8 hours, the shortest among the approved DORAs.

Development trajectory: Approved by the FDA in January 2022 for the treatment of adult insomnia at 25 mg and 50 mg doses. Phase 3 trials demonstrated improvements in polysomnographic sleep endpoints and, notably, in daytime functioning (Insomnia Daytime Symptoms and Impacts Questionnaire), a differentiation claim from the other approved DORAs [16].

Novelty: Low. The DORA mechanism is established. The daytime functioning endpoint is a clinical differentiation but not a novel mechanism.

Effect size: Moderate for insomnia. The daytime functioning improvement is a clinically meaningful differentiator within the DORA class but does not extend to antidepressant efficacy.

Promising potential: Low for MDD. The compound is positioned for insomnia and has not been advanced for depression indications.

Side-effect profile: Most common adverse events are somnolence, headache, and nausea. The shorter half-life (8 hours) relative to suvorexant and lemborexant produces less next-day impairment. No cataplexy reported [16].

Overall validation: Moderate to high for insomnia. Low for MDD.

Comparison to seltorexant: Daridorexant is the approved DORA pharmacokinetically closest to seltorexant (8-hour versus 2-hour half-life) but remains a dual antagonist without demonstrated antidepressant activity. Seltorexant's shorter half-life, OX2R selectivity, and MDD clinical data set it apart for the depression-with-insomnia indication. The common Johnson and Johnson ownership of both daridorexant (via Idorsia acquisition) and seltorexant creates a strategic portfolio context in which the two compounds address complementary indications.

12.4 Vornorexant (ORN-0829, TS-142)

Mechanism: Dual orexin receptor antagonist with rapid elimination kinetics (half-life 1.3 to 3.3 hours), pharmacokinetically similar to seltorexant [15]. Developed by Taisho Pharmaceutical and Orrion Therapeutics.

Development trajectory: Phase 2 clinical trials for insomnia have been completed. Results demonstrated improvements in latency to persistent sleep, wake after sleep onset, and self-reported sleep metrics at 5 to 30 mg doses. All adverse events were mild to moderate with no serious events reported. No suicide attempts or ideation were observed [15].

Novelty: Low. The DORA mechanism is not novel. The short-acting pharmacokinetic profile is a differentiator within the DORA class but does not represent mechanistic novelty.

Effect size: Moderate for insomnia endpoints in Phase 2. No depression data.

Promising potential: Moderate. The compound is in Phase 2 for insomnia and represents a potential short-acting DORA alternative to the longer-acting approved agents. No MDD program has been disclosed.

Side-effect profile: Phase 2 data show favorable tolerability with minimal next-day residual effects, consistent with the short half-life [15]. No cataplexy or serious events.

Overall validation: Low to moderate. Phase 2 insomnia data only.

Comparison to seltorexant: Vornorexant is the DORA pharmacokinetically most similar to seltorexant (short half-life, rapid elimination) but lacks the OX2R selectivity and the antidepressant clinical evidence that define seltorexant's positioning. The two compounds share the design philosophy of short-acting orexin receptor antagonism but diverge in selectivity (dual versus selective) and target indication (insomnia versus MDD with insomnia).

12.5 Filorexant (MK-6096)

Mechanism: Dual orexin receptor antagonist developed by Merck as a follow-on to suvorexant with an improved pharmacokinetic profile [18]. Half-life of approximately 4 to 6 hours.

Development trajectory: Phase 2 clinical trials were completed for insomnia and migraine prevention. The insomnia Phase 2 study demonstrated improvements in polysomnographic endpoints. A Phase 2 trial in diabetic peripheral neuropathic pain was also conducted. The compound has not been advanced to Phase 3 for any indication and is no longer in active development [18].

Novelty: Low. The mechanism is conventional DORA.

Effect size: Moderate for insomnia in Phase 2. A migraine prevention trial reported suggestive but non-definitive results. The compound was not studied in MDD.

Promising potential: Low. Development has been discontinued.

Side-effect profile: Phase 2 studies reported acceptable tolerability consistent with the DORA class. No serious events. Somnolence was the principal adverse event [18].

Overall validation: Low. The compound was discontinued after Phase 2 and serves primarily as a historical reference for the short-acting DORA concept.

Comparison to seltorexant: Filorexant represents an earlier attempt at a short-acting DORA that was not advanced. Seltorexant's success in reaching Phase 3 with positive results is attributable in part to the OX2R selectivity and the depression-with-insomnia indication, which provided a mechanistic and clinical rationale that the short-acting DORA approach (filorexant, vornorexant) did not have for insomnia alone.

12.6 Comparator summary

The five comparator compounds span the orexin receptor antagonist landscape from approved long-acting DORAs (suvorexant, lemborexant) through an approved intermediate-acting DORA (daridorexant) to developmental short-acting DORAs (vornorexant, filorexant). All five are dual receptor antagonists; none is OX2R-selective; and none has been studied in a dedicated MDD program with positive Phase 3 data.

Seltorexant occupies a unique position in this comparator landscape: it is the only selective OX2R antagonist in late-stage clinical development, the only orexin receptor antagonist with positive Phase 3 data in MDD, and the only compound in this class with demonstrated antidepressant efficacy through modulation of orexin-ergic hyperarousal and HPA axis function. The short half-life (2 to 3 hours) is shared with vornorexant and is shorter than all approved orexin antagonists, supporting a bedtime dosing paradigm with minimal next-day impairment. The OX2R selectivity provides a cleaner pharmacological profile with less theoretical risk of reward pathway modulation (through OX1R sparing) and more targeted HPA axis suppression (through selective OX2R blockade).

The principal question for the clinical positioning of seltorexant is whether the OX2R selectivity and the MDD indication represent sufficient differentiation from the approved DORAs to support regulatory approval and clinical adoption. The Phase 3 MDD3001 data (MADRS difference negative 2.6, $p = 0.007$) and the MDD3005 tolerability advantage over quetiapine XR (the current standard augmentation strategy) provide the evidence base for this differentiation. The compound addresses an unmet need in MDD with insomnia symptoms, a population with high treatment resistance, poor quality of life, and limited pharmacological options that combine antidepressant and sleep-promoting effects without the metabolic and sedative burdens of atypical antipsychotic augmentation.

13. References

1. Bonaventure P, Shelton J, Letavic MA, et al. Characterization of JNJ-42847922, a selective orexin-2 receptor antagonist, as a clinical candidate for the treatment of insomnia. *J Pharmacol Exp Ther*. 2015;354(3):471-482.
2. Letavic MA, Bonaventure P, Carruthers NI, et al. Novel octahydropyrrolo[3,4-c]pyrrole orexin-2 receptor antagonists: structure-activity relationships leading to the discovery of JNJ-42847922. *Bioorg Med Chem Lett*. 2015;25(5):1092-1098.
3. World Intellectual Property Organization. WO2023163964A1: Solid state forms of seltorexant. Johnson and Johnson. Filed 2023.
4. Minerva Neurosciences / Johnson and Johnson. Seltorexant development program summary. AdisInsight drug profile. Accessed May 2026.
5. Sakurai T. The neural circuit of orexin (hypocretin): maintaining sleep and wakefulness. *Nat Rev Neurosci*. 2007;8(3):171-181.
6. Johnson PL, Molosh A, Fitz SD, Truitt WA, Shekhar A. Orexin, stress, and anxiety/panic states. *Prog Brain Res*. 2012;198:133-161.
7. Nollet M, Leman S. Role of orexin in the pathophysiology of depression: potential for pharmacological intervention. *CNS Drugs*. 2013;27(6):411-422.
8. Recourt K, de Boer P, Zuiker R, et al. The selective orexin-2 antagonist seltorexant (JNJ-42847922/MIN-202) shows antidepressant and sleep-promoting effects in patients with major depressive disorder. *Transl Psychiatry*. 2019;9(1):216.
9. Savitz A, Binneman B, Engelen S, et al. Efficacy and safety of seltorexant as adjunctive therapy in major depressive disorder: a phase 2b, randomized, placebo-controlled, adaptive dose-finding study. *Int J Neuropsychopharmacol*. 2021;24(12):965-976.
10. Johnson and Johnson. Johnson and Johnson pivotal study of seltorexant shows statistically significant and clinically meaningful improvement in depressive symptoms and sleep disturbance outcomes. Press release. May 29, 2024.

11. Johnson and Johnson. Johnson and Johnson's investigational seltorexant shows numerically higher response in patients with depression with insomnia symptoms, with fewer side effects compared to quetiapine XR. Press release. September 2025.
12. Recourt K, Zuiker R, de Boer P, et al. Treatment effect and safety of seltorexant as monotherapy for patients with major depressive disorder: a randomized, placebo-controlled clinical trial. *Mol Psychiatry*. 2024. Published online December 11, 2024.
13. De Boer P, Drevets WC, Roffel AF, et al. A randomized phase 2 study to evaluate the orexin-2 receptor antagonist seltorexant in individuals with insomnia without psychiatric comorbidity. *J Psychopharmacol*. 2018;32(6):668-677.
14. Van der Ark PD, de Boer P, et al. Effects of multiple-dose administration of seltorexant on safety, tolerability, pharmacokinetics, and next-day cognitive function in healthy subjects. *Sleep*. 2019;42(Suppl 1):A136.
15. Sowa-Kucma M, Panczyszyn-Trzewik P, Misztak P, et al. Characteristics of seltorexant: innovative agent targeting orexin system for the treatment of depression and anxiety. *Molecules*. 2023;28(8):3575.
16. Muehlan C, Hoch M, Dingemanse J. The orexin story and orexin receptor antagonists for the treatment of insomnia. *J Sleep Res*. 2023;32(4):e13902.
17. MedChemExpress. Seltorexant (JNJ-42847922) product data sheet. Accessed May 2026.
18. Winrow CJ, Gotter AL, Cox CD, et al. Pharmacological characterization of MK-6096, a dual orexin receptor antagonist for insomnia. *Neuropharmacology*. 2012;62(2):978-987.
19. Kim HY, Cho YJ. Pharmacological review of seltorexant for the treatment of insomnia and major depressive disorder. *Transl Clin Pharmacol*. 2024;32(1):e5.
20. Janto K, Prichard JR, Bhatt P. An update on dual orexin receptor antagonists and their potential role in insomnia therapeutics. *J Clin Sleep Med*. 2018;14(8):1399-1408.
21. Bonaventure P, Yun S, Johnson PL, et al. A selective orexin-1 receptor antagonist attenuates stress-induced hyperarousal without hypnotic effects. *J Pharmacol Exp Ther*. 2015;352(3):590-601.

This monograph is provided for research use only. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. Seltorexant is an investigational compound that has not received regulatory approval in any jurisdiction. The compound is available only as research-grade material from chemical suppliers or through enrollment in sponsored clinical trials. Investigators should consult their local regulatory authority and institutional review board before any human research application. All dose ranges and clinical observations described in this monograph are derived from published clinical trials and should not be interpreted as dosing recommendations.